Comparative pulmonary function and pharmacokinetics of fluticasone propionate and salmeterol xinafoate delivered by two dry powder inhalers to patients with asthma

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 24, Issue 5, 2011, Pages 245-252

  Harrison, Lester I ^a   Novak, Christopher C ^a   Needham, Michael J ^b   Ratner, Paul ^c  

^a 3M COMPANY   (United States)

^b 3M Drug Delivery Systems   (United Kingdom)

^c Sylvana Research   (United States)

Author keywords

asthma

Indexed keywords

CHARCOAL; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; LACTOSE; SALMETEROL XINAFOATE;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASTHMA; CLINICAL ARTICLE; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG SAFETY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INHALATION; LUNG FUNCTION; MALE; METERED DOSE INHALER; PARTICLE SIZE; POWDER INHALER; RANDOMIZED CONTROLLED TRIAL; SPIROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ALBUTEROL; ANDROSTADIENES; ASTHMA; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS;

EID: 80053518318     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2011.0884     Document Type: Article

References (23)

1. Islam N, and Gladki E: Dry powder inhalers (DPIs)-a review of device reliability and innovation. Int J Pharm. 2008;360:1-11.
2. Dolovich MB, and Dhand R: Aerosol drug delivery: developments indevice design and clinical use. Lancet. Available at: www.thelancet.com, published online November 1, 2010.
3. Telco MJ, and Hickley AJ: Dry powder inhaler formulation. Respir Care. 2005;50:1209-1227.
4. Voss A, and Finlay WH: Deagglomeration of dry powder pharmaceutical aerosols. Int J Pharm. 2002;248:39-50. (Pubitemid 35341408)
5. Newman SP, Wilding IR, and Hirst PH: Human lung deposition data: the bridge between in vitro and clinical evaluations for inhaled drug products? Int J Pharm. 2000;208:49-60.
6. Dunbar C, and Mitchell J: Analysis of cascade impactor mass distributions. J Aerosol Med. 2005;18:439-451. (Pubitemid 43038409)
7. USP General Chapter <601> Aerosols, Nasal Sprays, Metered-Dose Inhalers and Dry Powder Inhalers. United States Pharmacopeia-National Formulary. United States Convention, Rockville, MD; 2009.
8. American Thoracic Society Standardization of Spirometry 1994 Update. Am J Respir Crit Care Med. 1995;152:1107-1136.
9. Brutsche MH, Brutsche IC, Munawar M, Langley SJ, Masterson CM, Daley-Yates PT, Brown R, Custovic A, and Woodcook A: Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionateand healthy volunteers: a randomized crossover study. Lancet. 2000;356:556-561. (Pubitemid 30611861)
10. Falcoz C, Oliver R, McDowall JE, Ventresca P, Bye A, and Daley-Yates PT: Bioavailability of orally administered micronized fluticasone propionate. Clin Pharmacokinet 2000;39(Suppl 1):9-15.
11. Agertoft L, Laulund LW, Harrison LI, and Pedersen S: Influence of particle size on lung deposition and pharmacokinetics of beclomethasone dipropionate in children. Pediatr Pulmonol. 2003;35:192-199. (Pubitemid 36246156)
12. Harrison LI, Soria I, Cline AC, and Eckholm BP: Pharmacokinetic differences between chlorofluorocarbon and chlorofluorocarbon-free metered dose inhalers of beclomethasone dipropionate in adult asthmatics. J Pharm Pharmacol. 199;51:1235-1240.
13. Daley-Yates PT, Perkins DA, Thomas MJ, Gillett B, House KW, and Ortega HG: Pharmacokinetic, pharmacodynamic, efficacy, and safety data from two randomized double-blind studies in patients with asthma and an in vitro study comparing two dry-powder inhalers delivering a combination of salmeterol 50 mg and fluticasone propionate 250 mg: implications for establishing bioequivalence of inhaled products. Clin Ther. 2009;31:370-385.
14. Clearie KL, Williamson PA, Vaidyanathan S, Du Bois J, Nell H, and Lipworth BJ: Systemic bioavailability of hydrofluoroalkane formulations of fluticasone/salmeterol in healthy volunteers via pMDI alone and spacer. Br J Clin Pharmacol. 2010;69:637-644.
15. Ward JK, Man CY, Horton J, and Ventresca GP: Systemic dynamic responses to oral doses of salmeterol in healthy subjects-effect of activated charcoal. Am J Respir Crit Care Med. 1997;155:A346.
16. Bennett JA, Harrison TW, and Tatterersfield: The contribution of the swallowed fraction of an inhaled dose of salmeterol to its systemic effects. Eur Respir J. 1999:13:445-448. (Pubitemid 29086848)
17. Varum FJO, Merchant HA, and Basit AW: Oral modifiedrelease formulations in motion: the relationship between gastrointestinal transit and drug absorption. Int J Pharm. 2010;395:26-36.
18. Borgstrom L, and Nilsson M: A method for determination of the absolute pulmonary bioavailability of inhaled drugs: Terbutaline. Pharm Res. 1990;7:1068-1070. (Pubitemid 20366736)
19. Srichana T, Suedee R, Muanpanarai D, and Tanmanee N: The study of in vitro-in vivo correlation: pharmacokinetics and pharmacodynamics of albuterol dry powder inhalers. J Pharmacol Sci. 2005;94:220-230. (Pubitemid 40116385)
20. Aswania OA, Corlett SA, and Chrystyn H: Relative bioavailability of sodium cromoglycate to the lung following inhalation, using urinary excretion. Br J Clin Pharmacol. 1999;47:613-618. (Pubitemid 29257658)
21. Wang ZI, Grgic B, and Finlay WH: A dry powder inhaler with reduced mouth-throat deposition. J Aerosol Med. 2006;19:168-174. (Pubitemid 43993383)
22. Rebello CJ, Chandran SS,Morde N, et al. Evaluation of the rate and extent of pulmonary absorption after administration of two salmeterolHFApMDI formulations in healthy volunteers. Respir Drug Del. 2010, Book 2 of Abstracts; pp. 539-542.
23. Adams WP, Ahrens RC, Chen M-L, Chen ML, Christopher D, Chowdhury BA, Conner DP, Dalby R, Fitzgerald K, Hendeles L, Hickey AJ, Hochhaus G, Laube BL, Lucas P, Lee SL, Lyapustina S, Li B, O'Connor D, Parikh N, Parkins DA, Peri P, Pitcairn GR, Riebe M, Roy P, Shah T, Singh GJPP, Sharp SS, Suman JD, Weda M, Woodcock J, and Yu L: Demonstrating bioequivalence of locally acting orally inhaled drug products: Workshop summary report. J Aerosol Med Pul Drug Del. 2010;23:1-29.